Debra Miller

CEO Founder @Cureduchenne

Founded CureDuchenne in 2003, made initial investments into small biotech companies working to accelerate drug development towards a cure • Formed CureDuchenne Ventures, LLC in 2014, a venture philanthropy approach for how CureDuchenne accelerates science towards new treatments and a cure • Received FDA approval for Exondys51 by Sarepta Therapeutics in 2016, funded by a CureDuchenne Ventures grant, this was the first drug to treat Duchenne • Hosted first CureDuchenne FUTURES national conference in 2018, an annual event held to connect the Duchenne community • Received the 2020 Nonprofit of the Year award for CureDuchenne from the California 74th Assembly District • Launched CureDuchenne Link in 2021, a centralized data hub that connects information provided by the Duchenne and Becker community directly to researchers, to accelerate therapeutic discovery